Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Hims & Hers Health (NYSE: HIMS) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. Is Hims & Hers ...

Ozempic doesn't just reduce weight. Research shows GLP-1s also changes how much people spend on food, and the types of food ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and diabetes drugs exploding in popularity, even more expensive for Americans.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

COPENHAGEN - The CEO of obesity drugmaker Novo Nordisk and heads of other Danish companies met on Thursday with Denmark's ...

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

The CEO of obesity drug manufacturer Novo Nordisk and heads of other Danish companies were expected to discuss preparations ...

Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group said on Thursday after business leaders, including CEO ...

President-elect Donald Trump wants to buy the territory from Denmark, which says it’s not for sale. DealBook asked experts ...

These high-quality businesses have suffered recent share price setbacks. This writer thinks they're now worth considering for a Stocks and Shares ISA. The post 2 beaten-down shares to consider for a ...